Please try another search
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Peter Hendricks | - | 2022 | Member of Scientific Advisory Board |
Ian McDonald | 34 | 2019 | Co-Founder, CEO, President & Director |
Jeremy Fryzuk | 38 | 2020 | Independent Director |
Michael P. Bogenschutz | - | 2022 | Member of Scientific Advisory Board |
Jan Torleif Pedersen | 58 | 2022 | Chief Science Officer & Director |
Robert C. Malenka | - | 2022 | Member of Scientific Advisory Board |
Nils Christian Bottler | 36 | 2020 | Independent Director |
Herbert Y. Meltzer | - | 2022 | Member of Scientific Advisory Board |
David M. Weiner | 59 | 2023 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review